COMMUNIQUÉS West-GlobeNewswire

BriaCell Announces Proposed Effective Date of Share Consolidation
21/08/2025
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology [...]
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
21/08/2025
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s [...]
Applied StemCell Appoints Dolores Baksh, Ph.D., as Chief Executive Officer
21/08/2025
MILPITAS, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Applied StemCell , a genome engineering product and services company, announced today the appointment of Dolores Baksh, Ph.D., as Chief Executive Officer. Company [...]
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
21/08/2025
Partnership includes joint collaboration initiatives to improve precision medicine and accelerate innovation in cancer pathology BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI , a global leader [...]
Silo Pharma’s Alzheimer’s Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal
21/08/2025
Manuscript featured in leading open-access scientific journal Alzheimer’s Research & Therapy SARASOTA, FL, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified [...]
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
21/08/2025
TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
21/08/2025
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-631 in Healthy Volunteers SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a [...]
Synergy CHC Corp to Present at the 2025 Gateway Conference on September 4th
21/08/2025
WESTBROOK, Maine, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is confirmed to present at the 2025 Annual Gateway [...]
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
21/08/2025
CAMBRIDGE, Mass. and FRANKLIN, Tenn., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease [...]
L’intervention de la Croix-Rouge en réponse aux feux de forêt de 2025 est la plus vaste des dernières années au pays
21/08/2025
L’ampleur et la complexité des opérations dépassent celles en réponse à la pandémie de COVID-19 OTTAWA, 21 août 2025 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a annoncé aujourd’hui que les opérations en réponse aux [...]
Red Cross 2025 wildfires response is largest domestic operation in recent history
21/08/2025
Scale and complexity of wildfires operations surpass response to COVID-19 pandemic OTTAWA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross today announced that the 2025 wildfires response operation is the [...]
Beta Bionics Announces Participation at Upcoming Investor Conferences
21/08/2025
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at [...]
Valitor Announces Upcoming Presentations at the Ophthalmology Futures Retina Forum and Euretina Conference, Including New Data for its Long-Acting Anti-VEGF Drug Candidate for Wet AMD, VLTR-559
21/08/2025
New non-human primate (NHP) data for VLTR-559, a long-acting anti-VEGF therapy that could reduce the dosing frequency for the treatment of wet age-related macular degeneration (AMD) to twice-yearly, will be presented [...]
UroGen Pharma to Present at Upcoming Investor Conferences
21/08/2025
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Immuneering Announces $25 Million Private Placement
21/08/2025
CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a [...]
Catheter Precision Announces the Start of Enrollment for the LockeT Compare Study
21/08/2025
First patients have been enrolled Fort Mill, S.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced [...]
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for VG801 Gene Therapy for Stargardt Disease
21/08/2025
MUNICH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- VeonGen Therapeutics, a clinical-stage genetic medicine company developing next-generation gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has [...]
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
21/08/2025
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)
21/08/2025
LONDON and CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and [...]

Pages